Have an account? Log in.
I don't have an account.
According to a Bloomberg report, Trump may impose 100% tariffs on drugmakers without pricing deals, as part of a broader push to lower drug costs.
GSAT, XOM, CYCN, LLY, INTC were among the stocks seen trending on Wednesday, April 1, 2026.
Structure Therapeutics shares rose, likely driven by FDA approval of a competing obesity treatment, boosting sentiment.
https://www.cnbc.com/2026/04/01/eli-lilly-opposes-trump-mfn-drug-pricing-law-ceo-ricks-says.html
Eli Lilly shares surged after FDA approval of its oral obesity drug Foundayo, boosting growth prospects in the weight-loss market.
Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used
Centessa Pharma to be acquired by Eli Lilly for $8B. Analyst downgrades rating. Deal includes $6.3B in cash and potential $1.5B in milestones.
Eli Lilly (LLY) shares rallied after finding support at a formed resistance level. They may hit resistance at a former support level.
U.S. stocks bounce sharply on Tuesday as lower Treasury yields and Trump's signals of a potential Iran deal lifted sentiment, with the S&P 500 gaining 1.8% and tech leading.
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.